U.S. Drug Administration approves long-acting antibody AstraZeneca Evusheld (AZD7442)
AstraZeneca’s Evusheld is a long-acting combination of antibodies (tixagevimab and cilgavimab) approved by the U.S. Drug Administration (FDA) for emergency use to prevent COVID-19. The first shipments are expected to be available soon.
Related news
Medicines, yes, but we don’t look for healing on the Internet
In the case of a health complaint they have not…
Read more >
BENU and Foglaljorvost.hu signed a cooperation agreement
Hungary’s best-known pharmacy network and the country’s largest healthcare appointment…
Read more >
It is being renewed, which is why the Nébih antibiotic use notification system has stopped
Evaluating last year’s experience, Nébih introduces several innovations in the…
Read more >
More related news >
Related news
HEINEKEN Hungária Zrt. will start the festival season in Sopron on May 11.
The SopronFest, held for the first time in 2023, proved:…
Read more >
Auchan comes up with an unusual sale
There is serious competition between store chains to retain customers.…
Read more >
The MRSZ calls for industry cooperation and an action plan
At the request of the MRSZ, EY prepared a study…
Read more >
){kind=link}